Human Papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Human Papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2019’, provides an overview of the Human Papillomavirus (HPV) Associated Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer

– The report reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Human Papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects

– The report assesses Human Papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abion Inc

Abivax SA

Admedus Ltd

Advaxis Inc

Antiva Biosciences Inc

Apimeds Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Avalia Immunotherapies Ltd

Beijing Recreation Guards Biotechnology Co Ltd

BioMed Valley Discoveries Inc

BioNTech SE

BlueSky Vaccines KG

Cellid Co Ltd

Chain Biotechnology Ltd

Chengdu Institute of Biological Products Co Ltd

Cue Biopharma Inc

Denceptor Therapeutics Ltd

Elicio Therapeutics

Etubics Corp

EyeGene Inc

Genexine Inc

Gilead Sciences Inc

Hookipa Pharma Inc

iBio Inc

Immunomic Therapeutics Inc

IMV Inc

Innovene

Inovio Pharmaceuticals Inc

Inthera Bioscience AG

Iovance Biotherapeutics Inc

ISA Pharmaceuticals BV

Ispin Inc

Johnson & Johnson

Juno Therapeutics Inc

Merck & Co Inc

Merck KGaA

OncoNano Medicine Inc

Onconova Therapeutics Inc

Oxford Vacmedix UK Ltd

Papivax LLC

Pathovax LLC

PDS Biotechnology Corp

Profectus BioSciences Inc

Redbiotec AG

Rottapharm Biotech Srl

Rubius Therapeutics Inc

Selecta Biosciences Inc

Shanghai Bovax Biotechnology Co Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shantha Biotechnics Pvt Ltd

Shuttle Pharmaceuticals Inc

Sierra Oncology Inc

TCRCure Biotech Co Ltd

Theravectys SA

THEVAX Genetics Vaccine USA Inc

Touchlight Genetics Ltd

Transgene SA

UbiVac LLC

Vaccibody AS

Vault Pharma Inc

Vaxart Inc

Vectorite Biomedical Inc

ViciniVax BV

Vir Biotechnology Inc

Virion Therapeutics LLC

Virometix AG

VLP The Vaccines Company SL

Xiamen Innovax Biotech Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Human Papillomavirus (HPV) Associated Cancer - Overview 6

Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development 7

Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 19

Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 28

Human Papillomavirus (HPV) Associated Cancer - Drug Profiles 52

Human Papillomavirus (HPV) Associated Cancer - Dormant Projects 275

Human Papillomavirus (HPV) Associated Cancer - Discontinued Products 278

Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones 279

Appendix 291

List of Tables

List of Tables

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Abion Inc, H2 2019

Human Papillomavirus (HPV) Associated Cancer – Dormant Projects, H2 2019

Human Papillomavirus (HPV) Associated Cancer – Dormant Projects, H2 2019 (Contd..1), H2 2019

Human Papillomavirus (HPV) Associated Cancer – Dormant Projects, H2 2019 (Contd..2), H2 2019

Human Papillomavirus (HPV) Associated Cancer – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports